Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Instil Bio (Uk) Limited is actively prosecuting a portfolio within the Biotechnology & Pharmaceuticals technology area, currently managing 4 pending office actions. These actions are distributed across 3 distinct examiners and 3 distinct art units, showing a level of diversification in the review process. This spread suggests that the company's intellectual property covers several specialized areas or is being evaluated by multiple teams within the patent office, requiring a coordinated strategy across different administrative units.
The examiner with the highest workload in this portfolio is OUSPENSKI, ILIA I, who is currently handling 2 busiest examiner pending office actions. This means that OUSPENSKI, ILIA I is responsible for 2 of the 4 total pending actions for the company. The remaining actions are split among the other distinct examiners, as indicated by the total count of 3 distinct examiners. This concentration of 2 actions with a single examiner makes OUSPENSKI, ILIA I a primary figure in the current prosecution efforts.
With 3 distinct art units involved, the 4 pending office actions are likely subject to varying technical standards and examination cultures. The fact that 3 distinct examiners are reviewing the work ensures that the company receives multiple perspectives on its applications, although the 2 actions assigned to OUSPENSKI, ILIA I represent a significant focal point. Managing these 4 pending office actions requires attention to the specific nuances of the 3 distinct art units to ensure consistent results across the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.5% | +20.4% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| KOLKER, DANIEL E | 1 | 49.8% | +64.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17843480 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | KOLKER, DANIEL E | 107d overdue |
| 18323342 | USE OF FUSION CONSTRUCTS FOR IL-2 INDEPENDENT T CELL THERAPY | PETERS, ALEC JON | — |
| 18316548 | CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | — |
| 17361621 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1641 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18323342 | USE OF FUSION CONSTRUCTS FOR IL-2 INDEPENDENT T CELL THERAPY | PETERS, ALEC JON | 1641 | §102§103§112DP | Non-Final OA | — | Pending | May 24, 2023 |
| 18316548 | CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | May 12, 2023 |
| 17843480 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | KOLKER, DANIEL E | 1645 | §103Other | Final Rejection | 107d overdue | Pending | Jun 17, 2022 |
| 17361621 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Jun 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial